### Table S1. Patients’ characteristics

| Variable                        | Development cohort | Validation cohort |
|---------------------------------|--------------------|-------------------|
| Number of patients              | 400                | 77                |
| Size of RD                       |                    |                   |
| RD=0cm                          | 121 (30.3%)        | 20 (26.0%)        |
| RD≤1cm                          | 102 (25.5%)        | 31 (40.3%)        |
| RD>1cm                          | 177 (44.2%)        | 26 (33.7%)        |
| Age                             | 54.4±8.9           | 53.8±7.8          |
| GOG performance status          |                    |                   |
| 0-1                             | 323 (80.7%)        | 55 (71.4%)        |
| 2                               | 66 (16.5%)         | 18 (23.4%)        |
| 3                               | 11 (2.8%)          | 4 (5.2%)          |
| Preoperative ascites volume (ml) | 2600±1680.6        | 2400±1540.9       |
| Preoperative CA125 level (U/ml) | 3300±689.5         | 3100±567.9        |
| Grade of tumor                  |                    |                   |
| 1                               | 27 (6.8%)          | 3 (3.9%)          |
| 2                               | 144 (36.0%)        | 25 (32.5%)        |
| 3                               | 229 (57.2%)        | 49 (63.6%)        |
| Histotype of tumor              |                    |                   |
| Serous                          | 259 (64.8%)        | 59 (76.6%)        |
| Endometriod                     | 47 (11.7%)         | 8 (10.4%)         |
| Muscinous                       | 4 (1.0%)           | 1 (1.3%)          |
| Clear cell                      | 5 (1.3%)           | 2 (2.6%)          |
| Adenocarcinoma, not otherwise specified | 85 (21.2%)   | 7 (9.1%)          |
| Status of lymph nodes           |                    |                   |
| Negative                        | 21 (5.3%)          | 12 (15.6%)        |
| Positive                        | 45 (11.2%)         | 20 (26.0%)        |
| Unknown                         | 334 (83.5%)        | 45 (58.4%)        |
| Median PFS (months)             | 17.8 (12.3-26.0)   | -                 |
| Median OS (months)              | 34.2 (26.0-52.5)   | -                 |

**Abbreviations:** RD, residual disease; GOG, Gynecologic Oncology Group; PFS, progression-free survival; OS, overall survival
**Table S2.** PCI model

| region             | LSS 0 | LSS 1 | LSS 2 | LSS 3 |
|--------------------|-------|-------|-------|-------|
| Central            | 0     | 1     | 2     | 3     |
| Right Upper        | 0     | 1     | 2     | 3     |
| Epigastrum         | 0     | 1     | 2     | 3     |
| Left Upper         | 0     | 1     | 2     | 3     |
| Left Flank         | 0     | 1     | 2     | 3     |
| Left Lower         | 0     | 1     | 2     | 3     |
| Pelvis             | 0     | 1     | 2     | 3     |
| Right Lower        | 0     | 1     | 2     | 3     |
| Right Flank        | 0     | 1     | 2     | 3     |
| Upper Jejunum      | 0     | 1     | 2     | 3     |
| Lower Jejunum      | 0     | 1     | 2     | 3     |
| Upper Ileum        | 0     | 1     | 2     | 3     |
| Lower Ileum        | 0     | 1     | 2     | 3     |

Notes: LSS 0 referred to no tumor; LSS 1 referred to the size of tumor less than 0.5cm; LSS 2 referred to the size of tumor less than 5cm; and LSS 3 referred to the size of tumor more than 5cm.
Figure S1. Progression-free survival and overall survival of patients with residual disease of ≤1 cm and >1 cm.